Alexey Larionov

List of Publications by Year
in descending order

62 papers	**3,519** citations	279798 **23** h-index	254184 **43** g-index
66 all docs	**66** docs citations	**66** times ranked	**6462** citing authors

#	Article	IF	Citations
1	Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases. Human Molecular Genetics, 2022, 31, 3001-3011.	2.9	9
2	Investigating the clinical, pathological and molecular profile of oncocytic adrenocortical neoplasms: a case series and literature review. Endocrine Oncology, 2021, 1, 33-44.	0.4	0
3	Genomic profiling of acute myeloid leukaemia associated with ataxia telangiectasia identifies a complex karyotype with wild‑type <i>TP53</i> and mutant <i>KRAS, G3BP1</i> and <i>IL7R</i>. Pediatric Blood and Cancer, 2020, 67, e28354.	1.5	4
4	Malta (MYH9 Associated Elastin Aggregation) Syndrome: Germline Variants in MYH9 Cause Rare Sweat Duct Proliferations and Irregular Elastin Aggregations. Journal of Investigative Dermatology, 2019, 139, 2238-2241.e6.	0.7	5
5	Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. The Lancet Gastroenterology and Hepatology, 2018, 3, 489-498.	8.1	87
6	PO-061 Exploring heritable predisposition to paediatric rhabdomyosarcomas. ESMO Open, 2018, 3, A250.	4.5	1
7	Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. Frontiers in Oncology, 2018, 8, 89.	2.8	64
8	Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers. Journal of Steroid Biochemistry and Molecular Biology, 2017, 165, 228-235.	2.5	6
9	Novel Translational Research of Neo-adjuvant Endocrine Therapy. , 2016, , 189-216.		0
10	Prediction of Response to Aromatase Inhibitors in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 191-228.	0.1	1
11	Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. Journal of Clinical Oncology, 2015, 33, 2270-2278.	1.6	96
12	Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. Breast Cancer Research, 2015, 17, 35.	5.0	8
13	Resistance to Aromatase Inhibitors in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , .	0.1	4
14	Personalization of loco-regional care for primary breast cancer patients (part 2). Future Oncology, 2015, 11, 1301-1305.	2.4	3
15	Molecular Changes in Lobular Breast Cancers in Response to Neoadjuvant Letrozole. Annals of Oncology, 2014, 25, i5.	1.2	0
16	Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy. Cancer Research, 2014, 74, 5371-5376.	0.9	34
17	High prevalence of <i>GPRC5A</i> germline mutations in <i>BRCA1</i>-mutant breast cancer patients. International Journal of Cancer, 2014, 134, 2352-2358.	5.1	31
18	7LBA A 4 gene model can identify ER+HER2+ breast cancers unlikely to respond to neoadjuvant endocrine therapy. European Journal of Cancer, 2014, 50, S3.	2.8	0

#	Article	IF	Citations
19	Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation. Familial Cancer, 2013, 12, 129-132.	1.9	13
20	Use of Microarray Analysis to Investigate EMT Gene Signatures. Methods in Molecular Biology, 2013, 1046, 85-95.	0.9	2
21	Abstract PD3-2: Accurate and robust prediction of clinical response to aromatase inhibitors by two weeks of neoadjuvant breast cancer treatment. , 2013, , .		0
22	Abstract P5-09-01: Comprehensive gene assessment of estrogen receptor positive breast cancer reveals that HER2 plays an important role in resistance to neoadjuvant letrozole. , 2013, , .		0
23	Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenomics Journal, 2012, 12, 10-21.	2.0	50
24	Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Research, 2012, 14, 201.	5.0	76
25	Direct integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis. BMC Medical Genomics, 2012, 5, 35.	1.5	53
26	High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. International Journal of Cancer, 2012, 130, 2867-2873.	5.1	58
27	Abstract P6-04-10: Comprehensive gene and protein assessment of the role of Her2 in the response to neoadjuvant Letrozole suggests patients without amplification may also benefit from anti-Her2 treatment. , 2012, , .		0
28	Abstract P6-04-09: Lack of response to aromatase inhibitors involves distinct mechanisms. , 2012, , .		0
29	Abstract P3-06-23: Predicting response to neoadjuvant letrozole. , 2012, , .		0
30	Molecular effects of oestrogen deprivation in breast cancer. Molecular and Cellular Endocrinology, 2011, 340, 127-136.	3.2	13
31	Bridging the Gap Between Translational Research and Clinical Application. Journal of the National Cancer Institute Monographs, 2011, 2011, 134-137.	2.1	5
32	S1-8: Molecular Signaling Distinguishes Early ER Positive Breast Cancer Recurrences Despite Adjuvant Tamoxifen.. , 2011, , .		6
33	The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene, 2010, 29, 4838-4847.	5.9	87
34	Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Research, 2010, 12, R52.	5.0	72
35	Abstract P4-02-02: Epidermal Growth Factor Receptors (ErbB/HER) and the Ligand Neuregulin 1 (NRG1) Increase in Breast Tumors during Short Time Endocrine Treatment. , 2010, , .		0
36	Abstract P4-02-03: Gene Copy Number Alterations Related to mRNA and miRNA Expression in Endocrine Resistant Breast Cancers. , 2010, , .		0

#	ARTICLE	IF	CITATIONS
37	Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to Letrozole. Journal of Clinical Oncology, 2009, 27, 1382-1387.	1.6	93
38	Challenges in defining predictive markers for response to endocrine therapy in breast cancer. Future Oncology, 2009, 5, 1415-1428.	2.4	25
39	Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13820-13825.	7.1	1,257
40	miRNA Profiling of Endocrine-Resistant Breast Tumours.. , 2009, , .		0
41	Gene Expression Profiles of Endocrine Resistant Breast Tumours.. , 2009, , .		0
42	Predicting response and resistance to endocrine therapy. Cancer, 2008, 112, 689-694.	4.1	25
43	C35 overexpression defines subsets of human breast cancer and its immunoreceptor tyrosine-based activation motif represents a novel treatment target. Breast Cancer Research, 2008, 10, .	5.0	0
44	Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenetics and Genomics, 2007, 17, 813-826.	1.5	94
45	Aromatase inhibitors—Gene discovery. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 130-142.	2.5	24
46	Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Research, 2007, 9, R37.	5.0	109
47	A standard curve based method for relative real time PCR data processing. BMC Bioinformatics, 2005, 6, 62.	2.6	780
48	Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer, 2005, 5, 113.	2.6	125
49	Aromatase inhibitors: Cellular and molecular effects. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 83-89.	2.5	21
50	Prediction of hormone response in breast cancer by microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy with letrozole. Journal of Clinical Oncology, 2005, 23, 3025-3025.	1.6	3
51	Aromatase in skeletal muscle. Journal of Steroid Biochemistry and Molecular Biology, 2003, 84, 485-492.	2.5	46
52	Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues. Journal of Steroid Biochemistry and Molecular Biology, 2002, 81, 57-64.	2.5	31
53	Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2002, 105, 161-165.	1.1	51
54	Aromatase (CYP19) expression in tumor-infiltrating lymphocytes and blood mononuclears. Journal of Cancer Research and Clinical Oncology, 2002, 128, 173-176.	2.5	7

#	Article	IF	Citations
55	Expression of the genes of adenylate cyclase (AC) G-protein subunits in breast cancer (BC) tissue: connection with estrogen-dependency?. European Journal of Cancer, 1999, 35, S201.	2.8	0
56	Ability of lymphocytes infiltrating breast-cancer tissue to convert androstenedione. , 1998, 77, 485-487.		6
57	Androstenedione (A) conversion in lymphocytes infiltrating breast cancer (BC) tissue. European Journal of Cancer, 1998, 34, S83-S84.	2.8	0
58	Tumor lymphocytic infiltration, hormonal-metabolic status and aromatase gene expression in breast cancer. European Journal of Cancer, 1997, 33, S10.	2.8	0
59	Androstenedione conversion in lymphocytes infiltrating breast tumor tissue. Bulletin of Experimental Biology and Medicine, 1997, 124, 1008-1010.	0.8	0
60	Aromatase in breast cancer tissue ? localization and relationship with reproductive status of patients. Journal of Cancer Research and Clinical Oncology, 1996, 122, 495-498.	2.5	26
61	Activity of aromatase in breast cancer tissue: Role of the cell substrate. Bulletin of Experimental Biology and Medicine, 1995, 120, 1042-1045.	0.8	0
62	Androstenedione conversion in human peripheral blood lymphocytes. Bulletin of Experimental Biology and Medicine, 1994, 117, 516-518.	0.8	2